Aniket Saha
Pediatric Hematology-Oncology · Greenville, SCNPI 1871749176
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $339 and has fallen 79.2% since, to $71 in 2025.
Across 26 payments — averaging $50.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$248
- AstraZeneca$243
- Novo Nordisk$171
- Rigel Pharmaceuticals, Inc.$116
- E.r. Squibb & Sons, L.L.C.$114
- Pharmacyclics LLC, An Abbvie Company$110
- plus $301 from 10 others
Across 4 payments — averaging $74,019 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$212K
- Novartis$84K
What the payments were for
- Food & beverage$1,302100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 2 | $248 |
| AstraZeneca(2 entities) | 3 | $243 |
| Novo Nordisk | 4 | $171 |
| Rigel Pharmaceuticals, Inc. | 1 | $116 |
| E.r. Squibb & Sons, L.L.C. | 1 | $114 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $110 |
| Karyopharm Therapeutics Inc. | 1 | $71 |
| Novartis | 3 | $64 |
| Adaptive Biotechnologies Corporation | 1 | $34 |
| Pierre Fabre Pharmaceuticals, Inc. | 2 | $33 |
| Pfizer | 2 | $28 |
| Silvergate Pharmaceuticals, Inc. | 1 | $17 |
| CSL Behring | 1 | $16 |
| Bayer | 1 | $15 |
| Emmaus Medical, Inc. | 1 | $12 |
| Octapharma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,302 in reported general payments places this provider in the 55th percentile of 32 pediatric hematology-oncology providers in South Carolina.
See all pediatric hematology-oncology providers in South Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 26 | $556 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $515 |
| Hydromorphone Hcl | 15 | $314 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Greenville
- Alan AndersonGreenville$320K
- Howland CrosswellGreenville$14K
- Leslie GilbertGreenville$8K
- Brianna MurphyGreenville$4K
- Nichole BryantGreenville$4K
- Rebecca CookGreenville$1K
- Chandni DarganGreenville$924
- Stephen MartinGreenville$699
- William SchmidtGreenville$0
- Shayla BergmannBeaufort$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.